AstraZeneca PLC (AZN) Operating Margin: 23.69%
Is AstraZeneca PLC’s operating margin high or low?
AstraZeneca PLC's operating margin of 23.69% is 57% above its 5-year average of 15.08%, near the high end of its 5-year range (2.82%–23.69%).
As of Wednesday, June 17, 2026. 13.08% above its 12-month average of 20.95%.
AZN Operating Margin Chart
AZN Average Operating Margin Chart
AZN Current vs Average Operating Margin Chart
AZN Operating Margin Metrics
OPERATING MARGIN
23.69%
OPERATING MARGIN AVG TTM
20.95%
OPERATING MARGIN AVG 3Y
17.06%
OPERATING MARGIN AVG 5Y
15.08%
OPERATING MARGIN AVG 10Y
15.65%
OPERATING MARGIN AVG 15Y
15.98%
OPERATING MARGIN AVG 20Y
21.24%
CURRENT VS TTM AVG
+13.08%
CURRENT VS 3Y AVG
+38.84%
CURRENT VS 5Y AVG
+57.13%
CURRENT VS 10Y AVG
+51.41%
CURRENT VS 15Y AVG
+48.28%
CURRENT VS 20Y AVG
+11.54%
AZN Competitors' Operating Margin
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $275.88B | 23.69% | 20.95% | 17.06% | 15.08% |
| Merck & Co., Inc. (MRK)vs › | $285.24B | 27.59% | 33.84% | 25.86% | 23.98% |
| Novo Nordisk A/S (NVO)vs › | $193.39B | 45.21% | 42.74% | 42.98% | 42.70% |
| UnitedHealth Group Incorporated (UNH)vs › | $362.83B | 4.19% | 6.16% | 7.45% | 7.80% |
| Amgen Inc. (AMGN)vs › | $184.40B | 31.63% | 25.38% | 28.78% | 30.08% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $171.57B | 17.76% | 18.04% | 18.11% | 20.54% |
| AbbVie Inc. (ABBV)vs › | $390.87B | 27.60% | 24.54% | 25.94% | 26.75% |
| Gilead Sciences, Inc. (GILD)vs › | $155.75B | 38.26% | 22.76% | 25.11% | 25.54% |
| Abbott Laboratories (ABT)vs › | $154.08B | 18.17% | 17.21% | 17.41% | 17.71% |
| Pfizer Inc. (PFE)vs › | $147.73B | 23.45% | 25.29% | 24.23% | 24.05% |
Operating Efficiency
Gross Margin
81.7%
Operating Margin
23.7%
AstraZeneca PLC Operating Margin Formula & Definition
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC Operating Margin FAQ
- What is the operating margin for AstraZeneca PLC (AZN)?
- The operating margin for AZN stock is 23.69%.
- Is AstraZeneca PLC's operating margin high or low?
- AstraZeneca PLC's operating margin of 23.69% is 57% above its 5-year average of 15.08%, near the high end of its 5-year range (2.82%–23.69%).
- What is the TTM average operating margin for AstraZeneca PLC (AZN)?
- The TTM average operating margin for AZN stock is 20.95%.
- What is the 3Y average operating margin for AstraZeneca PLC (AZN)?
- The 3Y average operating margin for AZN stock is 17.06%.
- What is the 5Y average operating margin for AstraZeneca PLC (AZN)?
- The 5Y average operating margin for AZN stock is 15.08%.
- What is the 10Y average operating margin for AstraZeneca PLC (AZN)?
- The 10Y average operating margin for AZN stock is 15.65%.
- What is the 15Y average operating margin for AstraZeneca PLC (AZN)?
- The 15Y average operating margin for AZN stock is 15.98%.
- What is the 20Y average operating margin for AstraZeneca PLC (AZN)?
- The 20Y average operating margin for AZN stock is 21.24%.
AstraZeneca PLC Operating Margin History
| DATE | OPERATING MARGIN |
|---|---|
| 2025-12-31 | 23.40% |
| 2024-12-31 | 18.50% |
| 2023-12-31 | 17.88% |
| 2022-12-31 | 8.47% |
| 2021-12-31 | 2.82% |
| 2020-12-31 | 19.39% |
| 2019-12-31 | 11.99% |
| 2018-12-31 | 15.33% |
| 2017-12-31 | 16.37% |
| 2016-12-31 | 21.31% |
| 2015-12-31 | 16.65% |
| 2014-12-31 | 8.05% |
| 2013-12-31 | 14.38% |
| 2012-12-31 | 29.13% |
| 2011-12-31 | 38.09% |
| 2010-12-31 | 34.55% |
| 2009-12-31 | 35.19% |
| 2008-12-31 | 28.94% |
| 2007-12-31 | 27.38% |
| 2006-12-31 | 31.03% |
| 2005-12-31 | 27.15% |
| 2004-12-31 | 21.22% |
| 2003-12-31 | 21.26% |
| 2002-12-31 | 22.45% |
| 2001-12-31 | 25.22% |
| 2000-12-31 | 20.23% |
| 1999-12-31 | 22.66% |
| 1998-12-31 | 21.44% |
| 1997-12-31 | 20.85% |
| 1996-12-31 | 19.45% |
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot